Hemostemix (CVE:HEM) Hits New 52-Week Low – What’s Next?
by Jessica Moore · The Cerbat GemHemostemix Inc. (CVE:HEM – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as C$0.06 and last traded at C$0.07, with a volume of 70000 shares trading hands. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The company has a debt-to-equity ratio of -99.52, a quick ratio of 0.48 and a current ratio of 1.54. The firm has a fifty day simple moving average of C$0.08 and a two-hundred day simple moving average of C$0.09. The firm has a market cap of C$13.19 million, a PE ratio of -2.59 and a beta of 0.25.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.